Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis.
Phase of Trial: Phase IV
Latest Information Update: 15 May 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 07 Jun 2017 Biomarkers information updated
- 06 Nov 2008 New trial record.